MEDICUS PHARMA LTD. Increase (Decrease) in Accounts Payable, Trade
MEDICUS PHARMA LTD. (MDCX) reported Increase (Decrease) in Accounts Payable, Trade of $3.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2026-08-12
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for the quarter ending 2026-06-30 was $4.41M.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for the quarter ending 2026-03-31 was -$1.26M, a 292.74% decline year-over-year.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for the quarter ending 2025-12-31 was $1.30M, a 127.51% increase year-over-year.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for the quarter ending 2025-09-30 was -$784.70K.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for fiscal 2025 was $923.55K, a 14.20% increase from fiscal 2024.
- MEDICUS PHARMA LTD. increase (decrease) in accounts payable, trade for fiscal 2024 was $808.75K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.15M 10-Q · filed 2026-08-12 | $4.45M derived: sum of 3 quarters · filed 2026-08-12 | $3.67M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$1.26M 10-Q · filed 2026-05-14 | $39.93K derived: sum of 2 quarters · filed 2026-05-14 | -$744.77K derived: sum of 3 quarters · filed 2026-05-14 | -$995.74K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $518.88K derived: sum of 2 quarters · filed 2026-03-25 | $267.92K derived: sum of 3 quarters · filed 2026-08-12 | $923.55K 10-K · filed 2026-03-25 |
| 2025-09-30 | -$784.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.04M derived: sum of 2 quarters · filed 2026-08-12 | -$380.03K 10-Q · filed 2025-11-14 | $192.96K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$250.96K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $404.67K 10-Q · filed 2026-08-12 | $977.66K derived: sum of 3 quarters · filed 2026-08-12 | |
| 2025-03-31 | $655.63K 10-Q · filed 2026-05-14 | $1.23M derived: sum of 2 quarters · filed 2026-05-14 | ||
| 2024-12-31 | $572.99K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $808.75K 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $235.76K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |